Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

The conversation discusses the use of 12.5mg cyproterone every other day for hair loss. There's a concern about reducing testosterone potentially increasing DHT and negatively affecting hair.

The user is on their 5th week of using pyrilutamide for hair loss without experiencing side effects and has noticed slight hair growth. They also use minoxidil with finasteride and dutasteride as part of their treatment regimen.

HMI 115 is being discussed as a potential hair loss treatment, with skepticism due to past disappointments like cosmeRNA, brezula, and pyrilutamide. The user is questioning if they should be hopeful for new developments in the next six years.

Researching the release of phase 2 trials for pyrilutamide, a potential hair loss treatment, and discussing other treatments such as Minoxidil, Finasteride, and RU58841.

A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.

The conversation is about seeking alternatives to finasteride for hair loss treatment due to concerns about sexual side effects, with pyrilutamide mentioned as a potential alternative.

The conversation discusses Pyrilutamide for hair loss, with skepticism about its legitimacy and mentions of an upcoming press release from Kintor. It also references ongoing trials and includes links for further information.

Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.

The user is considering using P5P to reduce high prolactin levels and is questioning if oral minoxidil could be contributing to the issue. They are also debating whether to switch from oral to topical minoxidil.

The conversation is about someone planning to start finasteride for hair loss and wanting to interpret pre-treatment blood panels to assess the risk of side effects like gynecomastia. They list various tests to measure hormone levels and other health indicators.

Kintor is accused of using fake pictures to promote their product, Pyrilutamide (KX826), which failed Phase 3 trials. Users express disappointment and note similar false advertising has occurred with finasteride and minoxidil.

PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.

The user observed some regrowth and longer baby hairs after one month of using finasteride, despite experiencing increased shedding. They noted no side effects except for clear semen.

The conversation discusses hair regrowth progress after 2.5 months using pyrilutamide and minoxidil. Participants note visible improvement in a short time.

Tae147 has shared results of using pyrilutamide, a 5% concentration topical solution applied twice daily, in combination with minoxidil, to reduce scalp itchiness and hair shedding. Other users have shared their experiences with the treatment, as well as questions about its availability on the market.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

Carpronium chloride 5% is a hair growth treatment in Japan, considered less effective than minoxidil or finasteride. Some users report moderate success with it, but its efficacy is not well-verified.

Hair loss discussion includes using fluridil (eucapil), minoxidil, and finasteride. One person takes 1 vial of fluridil daily and 1mg of finasteride every other day for effective treatment with minimal side effects.

The conversation is about the debate over the existence of Post-Finasteride Syndrome (PFS) and its symptoms, with some users skeptical about PFS and others discussing side effects like erectile dysfunction and gynecomastia from hair loss treatments like finasteride. Specific treatments mentioned include finasteride, viagra, and a joke about using a popsicle stick for erectile support.

PP405 shows some hair growth after 4 weeks, but results are debated and expectations should be tempered. Some users compare it to minoxidil or finasteride, questioning its effectiveness and commercialization timeline.

Pyrilutamide is believed to be more effective than RU58841 and 1 mg finasteride in treating hair loss, with no systemic hormonal effects and the potential to block more than 31% of scalp DHT. It may also antagonize scalp testosterone due to its action as an androgen receptor antagonist.

The user experienced initial success with topical finasteride 0.025% and melatonin but noticed rapid hair thinning after three months. They are considering switching to a higher dose of topical finasteride or oral finasteride, as advised by others, while being cautious about potential side effects.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

The user is taking a 2-in-1 pill containing 1mg finasteride and 3mg minoxidil daily, noticing some hair thickening and new hair growth but minimal progress at the back of the head. They are considering adding topical minoxidil or increasing dosage and are unsure if they should change their routine or wait for more results.

User noticed receding temples, used minoxidil and microneedling with positive results. Added saw palmetto and eucapil, experienced shedding and thinner hairline, but no side effects.

The user's consideration of taking finasteride as a short-term treatment, while awaiting advances in medical technology such as Pyrilutamide and GT20029; other users' experiences with Finasteride, including potential side effects.

HMI-115 is a new drug developed by Bioinvent and licensed by Bayer, with mixed opinions on its potential effectiveness. Some users are skeptical and prefer proven treatments like Minoxidil, finasteride, and RU58841.

Koshine 826 (Pyrilutamide) has mixed reviews, with some users experiencing side effects like insomnia and others seeing minimal results. Concerns about the company's transparency and lack of progress photos are noted.

The user experienced significant hair shedding in the second week of using pyrilutamide, more so than with finasteride and minoxidil, and reported a headache after the first application. They believe the treatment may be working but acknowledge it's too early to confirm results.